Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease

From the global burden of Cervical Cancer (CC), 85% occurs in developing countries, representing 12% of cancer in women. In Mexico CC ranks second in incidence and mortality among women. The National Institute of Cancer in Mexico (lNCAN) receives annually about 500 patients with CC, 80% of which are diagnosed with locally advanced disease. Furthermore, 10 to 20% of these present kidney deterioration. The main reason for kidney disease is ureteral obstruction, other causes include age and comorbidities, such as diabetes and hypertension. The standard treatment for locally advanced disease consi

Trial Details

NCT ID
NCT03101995
Phase
PHASE2
Sponsor
National Institute of Cancerología
Status
RECRUITING
Cancer Type
Cervical Cancer
Interventions
  • Gemcitabine
Locations (sample)
  • Mexico City, Mexico City, Mexico|19.42847,-99.12766

Key Eligibility Criteria

  • Patients who give their written consent to participate in the study.
  • Women, 18-70 years of age, considering the following criteria:
  • In women of childbearing age: i. Negative serum pregnancy test at baseline (14 days prior to the start of QT-RT).
  • ii. The patient must accept the use of any contraceptive method approved by the attending physician during the study and 12 weeks after the end of …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cervical Cancer Trials on Trialify →